Fluvoxamine in the treatment of anxiety-depressive spectrum disorders
- 23 April 2024
- journal article
- review article
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (6) , 101-109
Abstract
The RSCI and PubMed search databases have requested publications over the past 40 years on the search queries «fluvoxamine», «anxiety-depressive disorders», «anxiety», «depression», «comorbidity», devoted to the effectiveness of fluvoxamine in various variants of disorders of the anxiety-depressive spectrum, anxiety depressions. The data of the above studies indicate that fluvoxamine (Zovart San) in doses of 50-300 mg / day is a highly effective remedy for the treatment of not only anxiety depressions and genesis (psychogenic, organic, mixed, autochthonous-endogenous) and severity (up to psychotic), but also a wider range of anxiety-depressive disorders, including adaptation disorders, obsessive-compulsive disorder, somatized, dysmorphic, insomniac symptom complexes and eating disorders. A wide range of clinical effects of fluvoxamine is due to its main and additional mechanisms of action: blockade of serotonin reuptake, σ1-agonist activity and the effect on the metabolism of melatonin and neurosteroids catabolism.Keywords
This publication has 57 references indexed in Scilit:
- Neurosteroid dehydroepiandrosterone enhances activity and trafficking of astrocytic GLT‐1viaσ1receptor‐mediated PKC activation in the hippocampal dentate gyrus of ratsGlia, 2017
- A comparison of inpatients with anxious depression to those with nonanxious depressionPsychiatry Research, 2014
- Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cellsEuropean Journal of Pharmacology, 2014
- Sigma-1 receptor chaperone and brain-derived neurotrophic factor: Emerging links between cardiovascular disease and depressionProgress in Neurobiology, 2013
- Depersonalization disorder and anxiety: A special relationship?Psychiatry Research, 2012
- Vascular depression prevalence and epidemiology in the United StatesJournal of Psychiatric Research, 2012
- Cognition and depression: the effects of fluvoxamine, a sigma‐1 receptor agonist, reconsideredHuman Psychopharmacology: Clinical and Experimental, 2010
- A double-blind randomized study comparing imipramine with fluvoxamine in depressed inpatientsPsychopharmacology, 2004
- Fluvoxamine versus fluoxetine in major depressive episode: a double‐blind randomised comparisonHuman Psychopharmacology: Clinical and Experimental, 2003
- Lifetime and 12-Month Prevalence of DSM-III-R Psychiatric Disorders in the United StatesArchives of General Psychiatry, 1994